Journals / Turkish Journal of Medical Sciences / 2011 / Cilt: 41 - Sayı: 3

Association of ACP1 genotypes and clinical parameters in patients with metabolic syndrome*

Pages
533–541
Publication Date
2011-03-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Additionally, *A allele carriage affects body composition in women but not in men, and the presence of this allele might modulate serum cortisol levels as well as its suppressibility in both sexes, in an inverse manner.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Acid phosphatase locus 1 (ACP1) encodes a polymorphic enzyme and has potential implications for the development of metabolic syndrome (MS) by altering insulin sensitivity.
📊
Key Findings & Data:The aim of this study was to determine whether a relationship exists between ACP1 genotypes and various metabolic syndrome risk factors.
💡
Conclusion & Impact:Additionally, *A allele carriage affects body composition in women but not in men, and the presence of this allele might modulate serum cortisol levels as well as its suppressibility in both sexes, in an inverse manner.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Key words: Metabolic syndrome · ACP1 genotype · clinical variables

Abstract

Acid phosphatase locus 1 (ACP1) encodes a polymorphic enzyme and has potential implications for the development of metabolic syndrome (MS) by altering insulin sensitivity. The aim of this study was to determine whether a relationship exists between ACP1 genotypes and various metabolic syndrome risk factors. Materials and methods: We employed a PCR-RFLP based genotyping of ACP1 in a cohort of 70 patients with MS and 168 healthy individuals. Results: When compared to controls, genotypes associated with low enzyme activity were observed at significantly lower frequencies in both sexes. Of note, high enzyme activity genotypes were more common in patients with MS when compared with medium and low enzyme activity genotypes. *A allele frequency was not different between patients and controls even considering sex; however, there was a good correlation of the presence of the allele with body composition, serum cortisol levels and suppressibility of cortisol, particularly in women with MS. Conclusion: Our findings suggest that low enzyme activity genotypes seem to be associated with a protective effect for the development of MS. Additionally, *A allele carriage affects body composition in women but not in men, and the presence of this allele might modulate serum cortisol levels as well as its suppressibility in both sexes, in an inverse manner.

Özet

Acid phosphatase locus 1 (ACP1) encodes a polymorphic enzyme and has potential implications for the development of metabolic syndrome (MS) by altering insulin sensitivity. The aim of this study was to determine whether a relationship exists between ACP1 genotypes and various metabolic syndrome risk factors. Materials and methods: We employed a PCR-RFLP based genotyping of ACP1 in a cohort of 70 patients with MS and 168 healthy individuals. Results: When compared to controls, genotypes associated with low enzyme activity were observed at significantly lower frequencies in both sexes. Of note, high enzyme activity genotypes were more common in patients with MS when compared with medium and low enzyme activity genotypes. *A allele frequency was not different between patients and controls even considering sex; however, there was a good correlation of the presence of the allele with body composition, serum cortisol levels and suppressibility of cortisol, particularly in women with MS. Conclusion: Our findings suggest that low enzyme activity genotypes seem to be associated with a protective effect for the development of MS. Additionally, *A allele carriage affects body composition in women but not in men, and the presence of this allele might modulate serum cortisol levels as well as its suppressibility in both sexes, in an inverse manner.

🔖

Cite This Article

AKKİPRİK, M., SERTOĞLU, F. Ö., ÇAĞLAYAN, S., ARAL, C., ÖZIŞIK, G., ATABEY, Z., ÖZATA, M., ÖZER, S. A. (2011). Association of ACP1 genotypes and clinical parameters in patients with metabolic syndrome*. Turkish Journal of Medical Sciences, Cilt: 41 - Sayı: 3, 533–541. https://ajindex.com/articles/723594

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Bottini N, Bottini E, Gloria-Bottini F, Mustelin T. Low- molecular-weight protein tyrosine phosphatase and human disease: in search of biochemical mechanisms. Arch Immunol Th er Exp (Warsz) 2002; 50: 95-104. 2. Spencer N, Hopkinson DA, Harris H. Quantitative diff erences and gene dosage in the human red cell acid phosphatase polymorphism. Nature 1964; 201: 299-300. 3. Dissing J. Immunochemical characterization of human red cell acid phosphatase isozymes. Biochem Genet 1987; 25: 901–917. 4. Boivin P, Galand C. Th e human red cell acid phosphatase is a phosphotyrosine protein phosphatase which dephosphorylates the membrane protein band 3. Biochem Biophys Res Commun 1986; 134: 557-564. 5. Fuchs KR, Shekels LL, Bernlohr DA. Analysis of the ACP1 gene product: classifi cation as an FMN phosphatase. Biochem Biophys Res Commun 1992; 189: 1598-1605.
  2. Vogel W, Lammers R, Huang J, Ullrich A. Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation. Science 1993; 259: 1611-1614.
  3. Wo YY, McCormack AL, Shabanowitz J, Hunt DF, Davis JP, Mitchell GL et al. Sequencing, cloning, and expression of human red cell-type acid phosphatase, a cytoplasmic phosphotyrosyl protein phosphatase. J Biol Chem 1992; 267: 10856-10865. Executive summary of the third report of the Naıtional Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel UT). Expert Panel on Detection, and Treatment of High Blood Cholesterol in Adults. JAMA 2001; 285: 2486-297.
  4. Onat A, Ceyhan K, Başar O, Erer B, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels—a prospective and cross-sectional evaluation. Atherosclerosis 2002; 165: 285-292.
  5. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. National Heart, Lung, and Blood Institute; American Heart Association. Defi nition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientifi c issues related to defi nition. Arterioscler Th romb Vasc Biol 2004; 24: e13-8. Hopkinson DA, Spencer N, Haris H. Red cell acid phosphatase variants: a new human polymorphism. Nature 1963; 199: 969- 971. Lazaruk KDA. Molecular genetics of human red cell acid phosphatase. University of California, PhD dissertation (Professor Sensabaugh G.F.), Berkeley, 1995.
  6. John SWM, Weitzner G, Rozen R, Scriver CR. A Rapid Procedure for Extracting Genomic DNA from Leuko